Analysts Anticipate Edap Tms SA (EDAP) to Post $0.00 Earnings Per Share

Shares of Edap Tms SA (NASDAQ:EDAP) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Analysts have set a one year consensus target price of $6.50 for the company, according to Zacks. Zacks has also assigned Edap Tms an industry rank of 78 out of 255 based on the ratings given to its competitors.

EDAP has been the subject of several research reports. ValuEngine raised Edap Tms from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Edap Tms in a report on Friday, November 16th. Zacks Investment Research upgraded Edap Tms from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Thursday, January 3rd. Finally, TheStreet upgraded Edap Tms from a “d+” rating to a “c-” rating in a research note on Thursday, February 14th.

An institutional investor recently bought a new position in Edap Tms stock. Fosun International Ltd bought a new stake in shares of Edap Tms SA (NASDAQ:EDAP) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 170,627 shares of the medical equipment provider’s stock, valued at approximately $526,000. Fosun International Ltd owned about 0.59% of Edap Tms as of its most recent filing with the SEC. 10.07% of the stock is owned by institutional investors and hedge funds.

NASDAQ EDAP traded down $0.04 on Friday, reaching $2.92. 30,589 shares of the stock traded hands, compared to its average volume of 53,675. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.97 and a current ratio of 2.41. The firm has a market cap of $85.83 million, a P/E ratio of -292.00 and a beta of 1.60. Edap Tms has a 12 month low of $1.35 and a 12 month high of $4.25.

Edap Tms Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

Further Reading: What is a balanced fund?

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with's FREE daily email newsletter.